Austrian real-world experience with standard of care brexucabtagene autoleucel in patients with relapsed or refractory mantle-cell lymphoma. Journal Abstract - Guideline Central

Austrian real-world experience with standard of care brexucabtagene autoleucel in patients with relapsed or refractory mantle-cell lymphoma.

Published: 2026 Apr 17

Authors

, , , , , , , , , , , , , , , , , , ,

Abstract

Mantle-cell lymphoma (MCL) represents a rare B-cell malignancy with a challenging treatment situation in the case of relapsed or refractory (r/r) disease. Brexu-cel as first approved chimeric antigen receptor T-cell (CART) therapy revolutionized the therapeutic landscape and outcome in r/r MCL patients.

Keywords: Mantle cell lymphoma, chimeric antigen receptor T cells, real-world evidence

Source

Transplantation and cellular therapy

Publication Type

Journal Article

Language

English

PubMed ID

42002230

You rely on Guideline Central for transparency

Guideline Central and select third party use “cookies” on this website to enhance the user experience.

This technology helps us gather statistical and analytical information to optimize the relevant content for you.

The user also has the option to opt-out which may have an effect on the browsing experience.